India rejects Pfizer’s patent application for arthritis drug

India rejects Pfizer’s patent application for arthritis drug

FPJ BureauUpdated: Friday, May 31, 2019, 10:42 PM IST
article-image

New Delhi :  India’s patent office has again rejected US drug major Pfizer’s new patent application for its rheumatoid arthritis medicine, tofacitinib, citing it did not enhance the efficacy of the existing approved drug.

The decision assumes significance as multi-national drug companies have alleged that India’s intellectual property rights (IPR) regime is not in compliance with the global norms.

“The invention disclosed and claimed in the instant application… is not considered as an invention under the provisions of the Act,” Assistant Controller of Patents and Designs Bharat N S said in an order.

The Intellectual Property Appellate Board (IPAB) in October last year set aside an order by the patent office which rejected Pfizer’s patent for a new formula of the drug and directed it to re-consider the application.

Quoting a Supreme Court judgement, the order said that the applicant would have to establish the therapeutic enhanced efficacy of the claimed compound over the base compound.

“For the purposes of this clause, salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substances shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy,” he said. When contacted, Pfizer said the company’s base patent for Tofacitinib remains valid in India.

Pfizer remains committed to innovation and the long-term viability of its research and development programmes for the benefit of patients and healthcare practitioners in India and across the world, it said.

RECENT STORIES

Game-Changing Alliance: Ambani's Reliance Ventures Into Adani's Power For The First Time; Acquires...

Game-Changing Alliance: Ambani's Reliance Ventures Into Adani's Power For The First Time; Acquires...

SRM Contractors IPO Subscribed 86.57 Times On Last Day Of Bidding

SRM Contractors IPO Subscribed 86.57 Times On Last Day Of Bidding

Tax-Saving Tip From Zerodha CEO Nithin Kamath: 'If You're Married And Hindu..."; Here's How To Save...

Tax-Saving Tip From Zerodha CEO Nithin Kamath: 'If You're Married And Hindu...

Holy Cities Like Ayodhya, Varanasi Attracting Big Retail Brands: Report

Holy Cities Like Ayodhya, Varanasi Attracting Big Retail Brands: Report

A Big Relief For Byju's: NCLT Rejects Investor Plea To Stay Byju's Rights Issue EGM On March 29 Amid...

A Big Relief For Byju's: NCLT Rejects Investor Plea To Stay Byju's Rights Issue EGM On March 29 Amid...